Quick answer
What is the research profile of sermorelin? Sermorelin is the 29-residue GHRH (1-29) amide, formula C149H246N44O42S, average mass about 3,357.9 g/mol (monoisotopic about 3,355.82 Da), supplied as a lyophilized powder at ≥98% HPLC purity and stored refrigerated or frozen, protected from heat, moisture and light. It has no cysteine, a net charge near +4 at neutral pH, and weak points at Met27, Asn8 and the N-terminal Tyr-Ala pair.
This is a reference sheet, not an argument. It collects the identity fields from the product page, derives the numbers that follow from them, and lists the stability sites with their source. It is meant to be checked against a certificate of analysis, a mass spectrum and a bench notebook. For laboratory research use only; not for human consumption.
Identity card
This profile gathers the numbers a laboratory needs on one page: what the molecule is, what it is made of, what its mass spectrum should look like, how it is supplied and what sets the limits of its stability. Everything in the first table comes from the live sermorelin product page; the derived values that follow are arithmetic from that formula and sequence, shown so that they can be checked. For biology and history, see the overview.
| Field | Value | Source |
|---|---|---|
| Name used on the page | Sermorelin; GHRH (1-29) analog | Product page |
| Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg (29 residues) | Product page |
| One-letter code | YADAIFTNSYRKVLGQLSARKLLQDIMSR | Derived from the sequence |
| Molecular formula | C149H246N44O42S | Product page |
| Supplied form | Lyophilized powder, sealed clear glass research vial | Product page |
| Sizes | 5 mg and 10 mg | Product page |
| Purity | ≥98% by HPLC | Product page |
| Storage | Refrigerate at 2–8 °C; −20 °C for long-term; protect from heat, moisture and light | Product page |
| Counterion | Not stated on the page | Check the certificate |
Composition by residue
Counting the sequence gives the composition below. It is the starting point for anything that depends on the amino acids present, such as hydrolysis-based amino acid analysis, charge estimates and extinction coefficients.
| Residue | Count | Residue | Count | Residue | Count |
|---|---|---|---|---|---|
| Leu (L) | 4 | Ser (S) | 3 | Arg (R) | 3 |
| Ala (A) | 3 | Tyr (Y) | 2 | Asp (D) | 2 |
| Ile (I) | 2 | Lys (K) | 2 | Gln (Q) | 2 |
| Phe (F) | 1 | Thr (T) | 1 | Asn (N) | 1 |
| Val (V) | 1 | Gly (G) | 1 | Met (M) | 1 |
The totals add to 29. The molecule has no tryptophan, cysteine or proline; the absence of cysteine means no disulfide bonds, so it has no oxidative folding to monitor, and the absence of tryptophan means UV absorbance at 280 nm comes from the two tyrosines alone. The elemental composition by mass, from the formula and standard atomic masses, is approximately carbon 53.3%, hydrogen 7.4%, nitrogen 18.4%, oxygen 20.0% and sulfur 1.0%. The nitrogen figure is the one that matters for nitrogen-based content assays, which are used to estimate net peptide content.
Mass and charge-state arithmetic
A mass spectrum of a peptide this size shows a series of multiply protonated ions. The table gives expected positions, calculated from the formula; instruments report measured values and a few parts per million of deviation is normal for high-resolution instruments.
| Quantity | Value | Basis |
|---|---|---|
| Average molecular mass | about 3,357.9 g/mol | Standard atomic masses |
| Monoisotopic mass | about 3,355.82 Da | Most abundant isotope of each element |
| [M+2H]2+ (monoisotopic) | m/z about 1,678.92 | (M + 2 × 1.00728) ÷ 2 |
| [M+3H]3+ (monoisotopic) | m/z about 1,119.61 | (M + 3 × 1.00728) ÷ 3 |
| [M+4H]4+ (monoisotopic) | m/z about 839.96 | (M + 4 × 1.00728) ÷ 4 |
| [M+5H]5+ (monoisotopic) | m/z about 672.17 | (M + 5 × 1.00728) ÷ 5 |
| Methionine sulfoxide variant | +15.995 Da | One added oxygen |
| Deamidated variant | +0.984 Da | Asn to Asp or isoAsp, or Gln to Glu |
| Free-acid C-terminus | +0.984 Da | Amide replaced by acid |
Two points follow. First, deamidation and a free-acid C-terminus change the mass by the same 0.984 Da, so a +0.984 peak cannot by mass alone be assigned to one or the other; the retention time or fragmentation is needed. Second, for a 3 kDa peptide the monoisotopic peak is the strongest isotopic peak only approximately, so use the isotope pattern, not a single peak, to read the spectrum. HPLC versus mass spectrometry explains why both methods are needed, and how to read a COA covers the fields on a certificate.
Charge and absorbance estimates
The side chains give a rough picture of charge at neutral pH. Three arginines and two lysines carry positive charge, the free N-terminal amine adds one more, and two aspartates carry negative charge; the C-terminus is an amide and carries none. The net charge near pH 7 is therefore about +4, which is why the peptide is usually supplied as a salt and why it adsorbs readily to negatively charged glass. An approximate molar absorptivity at 280 nm from the two tyrosines, using the commonly used value of about 1,490 M-1cm-1 per tyrosine, is near 3,000 M-1cm-1; this is a low value, so absorbance at 280 nm is a weak method for dilute solutions and a good reason to confirm concentration by another method. These are estimates from the sequence and should be confirmed experimentally when concentration matters.
One further consequence of the charge is practical. A peptide that is positively charged at neutral pH will stick to negatively charged surfaces, including untreated glass and some plastics, and the loss is proportionally greatest at low concentrations. The labware literature on peptide adsorption documents that the choice of tube material changes recovery [4], so low-binding plastic is the default for dilute working solutions. If an assay reports results that drift with the vessel used, adsorption is the first explanation to test, before assuming degradation.
Concentration: formulas, not tables
Concentration arithmetic for any lyophilized peptide uses three relations, and the calculator applies them to the label mass and the diluent volume chosen in the protocol.
| Relation | Formula | Note |
|---|---|---|
| Moles | mass (g) ÷ 3,357.9 g/mol | Ceiling; weighed mass includes counterions and water |
| Molar concentration | moles ÷ volume (L) | Volume is chosen by the protocol |
| Mass concentration | molar concentration × 3,357.9 g/mol | Same quantity in µg/mL |
| Dilution | Cfinal = Cstock × Vtransferred ÷ Vtotal | For serial dilutions |
| Net peptide content | peptide mass ÷ weighed mass | From amino acid analysis or nitrogen content; a certificate may report it |
Peptide reconstitution volume calculations and how to reconstitute a lyophilized peptide walk through the bench steps.
Stability profile in one table
| Site | Reaction | Consequence | Reference |
|---|---|---|---|
| Met27 | Oxidation to sulfoxide | +16 Da; altered retention | Li et al. [1] |
| Asn8-Ser9 | Deamidation | +0.984 Da; isoAsp formation | Geiger and Clarke [2] |
| Asp3-Ala4, Asp25-Ile26 | Isomerization through a cyclic intermediate | Same mass; shifted retention | Geiger and Clarke [2] |
| Tyr1-Ala2 | Enzymatic cleavage in plasma | Inactive 3-29 type product; shown for the native 44-mer | Frohman et al. [3] |
| Whole peptide | Adsorption to surfaces | Loss at low concentration | Goebel-Stengel et al. [4] |
| Whole peptide | Freeze-concentration, aggregation | Loss of recoverable material | Manning et al. [5] |
The stability reviews and the sequence together justify the page's storage statement: the dry, cold, dark vial limits water, temperature and light, the three variables behind most of the reactions above. A longer discussion of persistence in plasma, medium and vial is in the comparison with the long-acting analog and the library pages on storage and reconstituted peptide lifetime.
Salt form and why it is on the profile
The page does not state a counterion, and a profile that leaves it blank is honest about a real gap. A trifluoroacetate salt is common for a peptide purified by reverse-phase HPLC, and a comparison of exchange methods found that partial to nearly complete replacement of trifluoroacetate was possible depending on the method [6]. In fetal rat osteoblast cultures, trifluoroacetate at 10-8 to 10-7 M reduced cell numbers and thymidine incorporation [7]. The takeaway for a profile is that the counterion belongs in the record for every lot used in a cell assay.
Quality specifications for peptide drug substances, reviewed by Vergote and colleagues, are set by compendial and regulatory documents that differ in their requirements for identity, related substances and content [8]; a research-grade certificate does not claim to meet those, and the sensible reading of "≥98% purity (HPLC)" is chromatographic purity only. The COA library lists published documentation, and understanding HPLC purity and sermorelin purity testing explain what that number covers. Related compounds are in the shop.
All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside a research setting.
Frequently asked questions
What is the sequence of sermorelin?
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg, 29 residues, as listed on the product page.
What is its molecular formula?
C149H246N44O42S, an average mass of about 3,357.9 g/mol and a monoisotopic mass of about 3,355.82 Da.
Does sermorelin contain cysteine?
No. It has no cysteine, so no disulfide bonds, and no tryptophan or proline.
What net charge does it carry at neutral pH?
About +4, from three arginines, two lysines and the N-terminal amine, less two aspartates; the C-terminus is an amide.
How does the peptide absorb UV light?
Only the two tyrosines absorb at 280 nm, giving a low molar absorptivity near 3,000, so UV is a weak method for dilute solutions.
Which mass peaks should I look for in LC-MS?
Multiply protonated ions, for example the 3+ ion near m/z 1,119.6 and the 4+ ion near 840.0, calculated from the monoisotopic mass.
Can a +0.984 Da peak be assigned by mass alone?
No. Deamidation and a free-acid C-terminus give the same shift, so retention time or fragmentation is needed.
What does the product page say about storage?
Refrigerate at 2–8 °C, or at −20 °C for long-term storage, and protect from heat, moisture and light.
Is the counterion stated?
Not on the product page; check the certificate or ask the supplier.
Related reading: CJC-1295 vs Sermorelin: Substitutions and Assay Design, Sermorelin Structure: Sequence, Acetate Salt and Synthesis, Sermorelin History: How GHRH (1-29) Was Discovered.
References
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785-794. PMID: 3805008
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-13. doi:10.1172/JCI112679
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Roux S, Zékri E, Rousseau B, Paternostre M, Cintrat JC, Fay N. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci. 2008;14(3):354-9. doi:10.1002/psc.951
- Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Cooper GJ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-83. doi:10.1152/ajpendo.1999.277.5.E779
- Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. doi:10.1002/psc.1167
